We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Cardiac Biomarker Assesses Heart Failure Prognosis

By LabMedica International staff writers
Posted on 02 Feb 2011
The levels of cardiac biomarkers in blood plasma predict the outcome for ambulatory outpatients with chronic heart failure and they more effectively risk-stratify such patients.

An assay to measure the amount of soluble growth stimulation expressed gene 2 protein (ST2) has been used to identify heart failure patients who are significantly more likely to have a heart transplant or to die during the three-year follow-up period.

In a multicenter cohort study, 1,141 heart failure patients were recruited from three tertiary-care centers, and were followed for a median of 2.8 years. More...
ST2 levels were measured at baseline from a blood sample taken at the enrollment of each patient into the study. The investigators conducted statistical analyses to predict outcomes by examining clinical presentation as well as the cardiac biomarkers ST2 and N-terminal brain natriuretic peptide (NT-proBNP).

The test used was the Presage ST2 Assay (Critical Diagnostics, San Diego, CA, USA). There were 267 (23% of patients) adverse events over the period, defined as the combined endpoint of death or cardiac transplantation. Patients in the highest ST2 tertile with levels above 36.3 ng/mL, had a markedly increased risk of adverse outcomes compared to the lowest tertile whose ST2 levels were equal to or less than 22.3 ng/mL. The unadjusted hazard ratio (HR) of 3.2 remained significant after multivariable adjustment; adjusted HR equaled 1.9. With each doubling of ST2, there was a 40% to 50% increased risk of death or cardiac transplantation in fully adjusted models.

Soluble ST2 reflects activity of an interleukin (IL-33) dependent cardioprotective signaling axis and is a diagnostic and prognostic marker in acute heart failure. ST2 signals the presence of adverse cardiac remodeling and fibrosis, which occurs in response to myocardial infarction (MI), ischemia, or worsening heart failure. Remodeling and fibrosis can also contribute to the development of future adverse events, such as secondary MI or sudden cardiac death, and to progression of heart failure.

Patrick A. Arensdorf, B.A., M.B.A., CEO of Critical Diagnostics, said, "The study found that more than one in seven chronic heart failure patients can be more appropriately risk-stratified when using ST2 and NT-proBNP in addition to the Seattle Heart Failure Model. By using the Presage ST2 Assay, clinicians may be able to target heart failure therapy more appropriately.” The study was published as an advance e-publication of the January 19, 2010 edition of Circulation: Heart Failure.

Related Links:
Critical Diagnostics



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.